Biotech | June 15, 2022
ProBioGen and ValenzaBio enter second service agreement
The new program includes upstream and downstream process development and large-scale GMP production.
The new program includes upstream and downstream process development and large-scale GMP production.
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Tislelizumab is now approved in nine indications in China
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
AstraZeneca also played a critical role in the global response to COVID-19.
Subscribe To Our Newsletter & Stay Updated
